1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. California >
  6. Xbiome Acquires Assembly Biosciences - Clinical-Stage M201 Program

M&A Deal Summary

Xbiome Acquires Assembly Biosciences - Clinical-Stage M201 Program

On April 25, 2022, Xbiome acquired life science company Assembly Biosciences - Clinical-Stage M201 Program from Assembly Bio

Acquisition Highlights
  • This is Xbiome’s 1st transaction in the Life Science sector.
  • This is Xbiome’s 1st transaction in the United States.
  • This is Xbiome’s 1st transaction in California.

M&A Deal Summary
Date 2022-04-25
Target Assembly Biosciences - Clinical-Stage M201 Program
Sector Life Science
Buyer(s) Xbiome
Sellers(s) Assembly Bio
Deal Type Divestiture

Target

Assembly Biosciences - Clinical-Stage M201 Program

San Francisco, California, United States
Assembly Biosciences' Clinical-Stage M201 Program is designed for patients with mild to moderate ulcerative colitis. M201 is comprised of a rationally designed consortium of commensal bacteria that were selected based on their ability to modulate ulcerative colitis-relevant cellular mechanisms in human cell-based assays and animal models.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Xbiome

Shenzhen, China
Category Company
Founded 2017
Sector Life Science
Employees200
DESCRIPTION

Xbiome is a clinical-stage AI-based microbiome drug development company dedicated to tackling unmet medical needs through various modalities of microbiome therapeutics including fecal microbiota transplantation (FMT), live biotherapeutic product (LBP), and small molecule microbiome modulator (SMMM). Xbiome was founded in 2017 and is based in Shenzhen China.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2022 M&A 1 of 1

Seller(S) 1

SELLER

Assembly Bio

South San Francisco, California, United States
Category Company
Founded 2005
Sector Life Science
Employees65
Revenue 29M USD (2024)
DESCRIPTION

Assembly Bio is a biopharmaceutical company developing innovative treatments for hepatitis B virus infection (HBV) and C. difficile-associated diarrhea (CDAD). Assembly Bio was founded in 2005 and is based in South San Francisco, California.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2022 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-05-19 Assembly Pharmaceuticals

Bloomington, Indiana, United States

Assembly Pharmaceuticals is a virology-focused biopharmaceutical company with a discovery platform and programs based on proprietary Core Protein Allosteric Modulators (CpAMs) for the treatment of viral infections, starting with hepatitis B (HBV).

Buy -
Mergr

Solution for

Product

Company

Legal